Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 164-172, September 2010

Prolonged QTc Interval in Cancer Therapeutic Drug Development: Defining Arrhythmic Risk in Malignancy

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd. EPN 2017, Bethesda, MD 20892

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Statement of Conflict of Interest: see page 171.

 Address reprint requests to Joanna Brell, MD, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd. EPN 2017, Bethesda, MD 20892.

PII: S0033-0620(10)00091-5

doi:10.1016/j.pcad.2010.05.005

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 164-172, September 2010

Article Tools

* Image Usage & Resolution